Recursion Pharmaceuticals (RXRX) stock rises after J.P. Morgan upgraded the biotech, citing a $1B+ sales potential for the ...

Recursion Pharmaceuticals, Inc. is rated a Sell due to cash burn, Q3 net loss of $162.25M and operational trends. Learn more ...

RXRX Stock jumps after JPMorgan upgrade and trial data boost, fueling investor optimism in Recursion’s AI drug discovery ...

Earlier in December 2025, Recursion Pharmaceuticals reported positive Phase 1b/2 TUPELO trial data for REC-4881 in familial adenomatous polyposis, showing rapid and durable reductions in polyp burden ...

'Mad Money' host Jim Cramer weighs in on stocks including: Recursion Pharmaceuticals and NuScale Power. Lawmakers split after viewing boat strike video: Democrat calls it 'one of the most troubling ...

The simulation hypothesis—the idea that our universe might be an artificial construct running on some advanced alien computer ...

Najat Khan, PhD, unpacks realistic timelines for AI-based drugs to make clinical impact and her priorities for Recursion as incoming CEO.

REC-4881 (4 mg QD) achieved rapid clinical activity, with 75% of evaluable patients showing reductions in total polyp burden and a 43% median ...

In 2025, Anthropic will grow from $1 billion to $9 billion in ARR (annual recurring revenue). OpenAI, meanwhile, will go from ...

Cornered in a part of Downtown Los Angeles swamped in contemporary art museums and performance centers, REDCAT has become a ...

One of the most significant insights from the study is that roboticists must engage both technically and physically with ...